Cargando…
In vitro safety “clinical trial” of the cardiac liability of drug polytherapy
Only a handful of US Food and Drug Administration (FDA) Emergency Use Authorizations exist for drug and biologic therapeutics that treat severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) infection. Potential therapeutics include repurposed drugs, some with cardiac liabilities. We report o...
Autores principales: | Charrez, Bérénice, Charwat, Verena, Siemons, Brian, Finsberg, Henrik, Miller, Evan W., Edwards, Andrew G., Healy, Kevin E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212738/ https://www.ncbi.nlm.nih.gov/pubmed/33786981 http://dx.doi.org/10.1111/cts.13038 |
Ejemplares similares
-
Heart Muscle Microphysiological System for Cardiac Liability Prediction of Repurposed COVID-19 Therapeutics
por: Charrez, Bérénice, et al.
Publicado: (2021) -
Isochoric supercooled preservation and revival of human cardiac microtissues
por: Powell-Palm, Matthew J., et al.
Publicado: (2021) -
Improved Computational Identification of Drug Response Using Optical Measurements of Human Stem Cell Derived Cardiomyocytes in Microphysiological Systems
por: Jæger, Karoline Horgmo, et al.
Publicado: (2020) -
Rational Polytherapy with Antiepileptic Drugs
por: Lee, Jong Woo, et al.
Publicado: (2010) -
Polytherapy and drug interactions in elderly
por: Gujjarlamudi, Hima Bindu
Publicado: (2016)